Palisade Bio Q2 FY26 net loss widens 280% to $10.57 million
PALI•Clinical trial update
- FDA cleared the IND for the Phase 2 ASCENTRA-UC trial in June; first patient enrollment is expected in the second half of 2026.
Q2 FY26 results and cash position
- Palisade Bio posted a net loss of $10.57 million in the quarter ended June 30, 2026, widening 280% year over year.
- Operating loss widened 311% to $11.7 million as operating expenses more than doubled to $12.2 million, led by R&D up 342% to $7.4 million.
- Revenue was $500,000, swinging from no revenue a year earlier on a milestone under the Newsoara co-development agreement.
- Cash, cash equivalents and restricted cash totaled $125.2 million at June 30, 2026; management sees funding through key Phase 2 readouts in 2027-2028.
